Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also produces, … Read more
Xlife Sciences AG (XLS) - Total Liabilities
Latest total liabilities as of June 2025: CHF232.84 Million CHF
Based on the latest financial reports, Xlife Sciences AG (XLS) has total liabilities worth CHF232.84 Million CHF as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Xlife Sciences AG - Total Liabilities Trend (2019–2024)
This chart illustrates how Xlife Sciences AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Xlife Sciences AG Competitors by Total Liabilities
The table below lists competitors of Xlife Sciences AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sound Financial Bancorp Inc
NASDAQ:SFBC
|
USA | $982.77 Million |
|
Digital Daesung Co. Ltd
KQ:068930
|
Korea | ₩165.89 Billion |
|
CBAK Energy Technology Inc
NASDAQ:CBAT
|
USA | $245.41 Million |
|
Voss Veksel og Landmandsbank ASA
OL:VVL
|
Norway | Nkr5.92 Billion |
|
Tempo Scan Pacific Tbk
JK:TSPC
|
Indonesia | Rp3.31 Trillion |
|
Eucatex S.A. Indústria e Comércio
SA:EUCA3
|
Brazil | R$1.95 Billion |
|
Anadolu Isuzu Otomotiv Sanayi ve Ticaret AS
IS:ASUZU
|
Turkey | TL16.47 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Xlife Sciences AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.00 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xlife Sciences AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xlife Sciences AG (2019–2024)
The table below shows the annual total liabilities of Xlife Sciences AG from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CHF235.11 Million | -3.57% |
| 2023-12-31 | CHF243.82 Million | -4.38% |
| 2022-12-31 | CHF255.00 Million | -5.15% |
| 2021-12-31 | CHF268.83 Million | +384.27% |
| 2020-12-31 | CHF55.51 Million | -2.00% |
| 2019-12-31 | CHF56.64 Million | -- |